ARTELO BIOSCIENCES INC C/WTS 25/06/2024(TO PUR COM) ARTLW 深 滬
等待開盤 03-26 09:30:00 美东时间
0.0056
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 0.0056
- 總市值 1.87万
- 52周最高 0.1498
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.005
- 委 比 0.00%
- 總股本 334.74万
- 歷史最高 1.25
- 量 比 0
- 振 幅 0.00%
- 歷史最低 0.005
- 每 手 1
- 風險率 0.00%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Artelo Biosciences Expanding Use Of ART27.13 In Muscle Preservation For Glucagon-Like Peptide-1 Receptor Agonist Therapy Patients
Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or
今天 04:13
Artelo Biosciences Expands Into Glaucoma Market With Fully Funded ART27.13 Clinical Trial Targeting Neuroprotection
Artelo Biosciences (NASDAQ:ARTL) has announced its entry into the ophthalmology space with a fully funded clinical study evaluating ART27.13 in glaucoma patients. The investigator-sponsored trial (IST) is backed by
03-18 20:08
Artelo Biosciences signs investigator-initiated clinical study to test ART27.13 in glaucoma patients
Artelo Biosciences signs investigator-initiated clinical study to test ART27.13 in glaucoma patients Artelo said it signed an investigator-initiated study agreement with Belfast Health and Social Care Trust to evaluate ART27.13 in patients with glaucoma or ocular hypertension. The pilot trial is des
03-18 19:41
Artelo Announces Third-Party Fully Funded Clinical Study Agreement to Evaluate ART27.13 in Glaucoma Patients
Artelo Biosciences enters a collaboration with Belfast Health and Social Care Trust to evaluate ART27.13, a peripherally selective synthetic cannabinoid, for treating glaucoma. Funded by Glaucoma UK and HSC R&D Division, the study aims to explore its effectiveness in lowering intraocular pressure without psychotropic side effects. ART27.13 has shown promise in preclinical studies and is being tested in a randomized, cross-over trial led by Profes...
03-18 11:41
Artelo Biosciences Enacts Reverse Stock Split Amid Strain
Artelo Biosciences ( ($ARTL) ) just unveiled an update. Artelo Biosciences exec...
03-18 05:18
Small-Cap healthcare stocks ranked by quant ratings after earnings season
As earnings season winds down, investors are shifting focus to updated quant ratings following the latest wave of corporate results. The scores offer a snapshot of how companies rank across key factor...
03-13 21:55
Artelo biosciences announces reverse stock split
Artelo Biosciences (ARTL) on Friday announced a 3-for-1 reverse stock split of the company’s common stock. The company’s common shares will begin trading on a split-adjusted basis on Nasdaq commencing...
03-06 22:35
Artelo Biosciences Announces 3-For-1 Reverse Stock Split, Effective March 10
Artelo Biosciences, Inc. (NASDAQ:ARTL) ("Artelo" or the "Company"), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain,
03-06 21:08
BRIEF-Artelo Biosciences Announces Reverse Stock Split
BRIEF-Artelo Biosciences Announces Reverse Stock Split March 6 (Reuters) - Artelo Biosciences Inc ARTL.O : ARTELO BIOSCIENCES ANNOUNCES REVERSE STOCK SPLIT ARTELO BIOSCIENCES INC - BOARD APPROVES 3-FOR-1 REVERSE STOCK SPLIT OF COMMON STOCK Source text: ID:nGNX4lqFzl Further company coverage: ARTL.O
03-06 21:03
Artelo Biosciences approves 3-for-1 reverse stock split
Artelo Biosciences approves 3-for-1 reverse stock split Artelo Biosciences Inc. said its board approved a 3-for-1 reverse stock split, with shares set to trade on a split-adjusted basis on the Nasdaq Capital Market starting March 10, 2026. The move will consolidate every three shares into one, with
03-06 21:00
